<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00989807</url>
  </required_header>
  <id_info>
    <org_study_id>EA-US-205-0122</org_study_id>
    <nct_id>NCT00989807</nct_id>
  </id_info>
  <brief_title>Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis</brief_title>
  <acronym>EAP</acronym>
  <official_title>Expanded Access for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection Who Have Limited Treatment Options and Are at Risk for Disease Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <brief_summary>
    <textblock>
      This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to
      its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa
      airway infection who have limited treatment options and are at risk for disease progression.
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Cystic Fibrosis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aztreonam lysine</intervention_name>
    <description>Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 6 years of age

          -  Patient has CF as diagnosed by one of the following:

          -  Documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test,
             or

          -  Two well characterized genetic mutations in the CFTR gene, or

          -  Abnormal nasal potential difference with accompanying symptoms characteristic of CF

          -  PA present in expectorated sputum or throat swab culture within 2 months prior to
             consent

          -  Patient must be able to provide written informed consent/assent prior to any study
             related procedure; parent/guardian must be able to give written informed consent as
             necessary prior to any study related procedure

          -  At high risk for disease progression as defined by one of the following patient
             populations:

          -  FEV1 ≤ 50 % predicted at the time of consent OR

          -  Completed participation in CP-AI-006 (through Visit 20). Patients who withdraw from
             CP-AI-006 prior to completing all courses of AZLI and all study visits will not be
             eligible for this protocol.

        Exclusion Criteria:

          -  Patients with any serious or active medical or psychiatric illness that, in the
             opinion of the investigator, would interfere with patient treatment, assessment or
             compliance with the protocol or dosing requirements

          -  Patients with hypersensitivity to any of the components of the drug product

          -  Currently enrolled in another clinical trial

          -  Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Calgary, Adult CF Clinic</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>T2N4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2009</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CF</keyword>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>EAP</keyword>
  <keyword>Expanded access</keyword>
  <keyword>AZLI</keyword>
  <keyword>Aztreonam lysine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aztreonam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

